Infectious Disease

AMA Announces CPT Codes for Novavax COVID-19 Vaccine

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

The AMA announced that the CPT code set has been updated to include codes for the COVID-19 vaccine developed by Novavax. According to a press release, the codes will take effect once they are approved by the FDA or approved for emergency use.

The preliminary codes were announced today to allow health systems to prepare their electronic systems in advance, the press release said.

Source: Adobe Stock

Previously, the AMA announced CPT codes for the COVID-19 vaccines developed by AstraZeneca, Johnson & Johnson, Moderna, and Pfizer-BioNTech before the vaccine was approved or the emergency approved.

“By relying on multiple manufacturers to manufacture various COVID-19 vaccine products, you can avoid potential supply disruptions and support the required dose volume.” Susan R. Bailey, MD, President of the AMA said in the press release. “However, the precise correlation of vaccinated patients with any of the available COVID-19 vaccines is critical to managing immunizations. This challenge is met with unique CPT codes that clinically differentiate each COVID-19 vaccine and provide the level of information accuracy required to ensure optimal vaccine distribution and administration. “

The CPT codes and long descriptors of the Novavax COVID-19 Category I vaccine are:

  • 91304: “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccine, recombinant spike protein nanoparticles, saponin-based adjuvant, preservative-free, 5 µg / 0.5 ml dosage, for intramuscular use; ”
  • 0041A: “Immunization administration by intramuscular injection of coronavirus 2 (SARS-CoV-2) with severe acute respiratory syndrome (coronavirus disease) [COVID-19]) Vaccine, recombinant spike protein nanoparticles, saponin-based adjuvant, preservative-free, 5 µg / 0.5 ml dosage; first dose; ” and
  • 0042A: “Immunization administration by intramuscular injection of coronavirus 2 (SARS-CoV-2) with severe acute respiratory syndrome (coronavirus disease) [COVID-19]) Vaccine, recombinant spike protein nanoparticles, saponin-based adjuvant, preservative-free, 5 µg / 0.5 ml dosage; second dose. “

ADD SUBJECT TO EMAIL ALARMS

Receive an email when new articles are published

Please enter your email address to receive an email when new articles are published . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles